RFK Jr. to Congress: US will remain at the center of the biotech world
HHS Secretary Robert F. Kennedy Jr. on Tuesday promised that the US will remain the leader in biotech innovation, even as China has added "huge amounts of money into this space." Speaking before the...
View ArticleFDA investigating Sarepta’s Duchenne gene therapy following patient deaths
The FDA announced Tuesday that it is looking into deaths due to liver failure following the administration of Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy ...
View ArticleBiogen unveils first spinal muscular atrophy data from Spinraza follow-on
Biogen shared that its next-generation spinal muscular atrophy RNA drug improved measures of neurodegeneration and motor function in an initial cut of data, and the company is planning to move the...
View ArticleBayer's BlueRock prioritizes neurology, eye programs, lays off about 50 staffers
Bayer subsidiary BlueRock Therapeutics is cutting back on some of its cell therapy work and laying off several dozen staffers. The company will restructure itself to support their neurology and...
View Article#ADA25: BrightGene seeks a partner for Zepbound-beating obesity shot
A Shanghai-based biotech, previously known as a generics and manufacturing player, posted mid-stage results suggesting its incretin drug might be one of the most powerful to have reached the clinic....
View ArticleArbutus regains rights to hepatitis B asset in China; Forte’s $75M offering
Plus, news about the Novo Nordisk Foundation, Assembly Biosciences, Cidara Therapeutics, Minovia and Celyad Oncology: Arbutus reacquires China rights to hepatitis B candidate: The company licensed the...
View ArticleKymera inks deal with Gilead as partnership with Sanofi faces a switch-up
Gilead has enlisted Kymera Therapeutics to develop a compound that it hopes can be part of the next wave of targeted breast cancer treatments. The partnership, which was announced Wednesday, centers ...
View ArticleTrump’s CDC nominee sidesteps Senate grilling on controversial changes
The Senate confirmation hearing for Susan Monarez, President Donald Trump’s second nominee for the next CDC director, featured few fireworks as she dodged questions about recent political moves at the...
View ArticleACIP will reassess cumulative vaccine effects, older shots
The newly reconstructed CDC vaccine advisory panel will examine the cumulative effects of the childhood vaccine schedule, in addition to shots that members say haven’t been reviewed in “more than seven...
View ArticleMedicare drug spending will slow due to IRA price negotiations, CMS...
Medicare spending on prescription drugs is expected to grow at a slower rate between 2028 and 2033 as a result of drug pricing provisions in the Inflation Reduction Act, a report by members of CMS' ...
View ArticleEndpoints Livestream: ACIP and the future of vaccines
Today on Post-Hoc Live, I'll be joined by senior editor Zachary Brennan and pharma reporter Max Bayer for a wide-ranging discussion about the remade Advisory Committee on Immunization Practices and how...
View ArticleNovartis strikes cardiovascular discovery deal with Flagship’s ProFound
Novartis has signed up proteomics specialist ProFound Therapeutics to pinpoint “previously unknown” proteins to be investigated as cardiovascular drugs and drug targets in a $25 million upfront deal....
View ArticleVor Bio bounces back with RemeGen autoimmune deal, $175M private placement
In an unexpected turn of events, Vor Bio is back on the fundraising trail and shifting focus to autoimmune disease, less than two months after it seemed to be at the end ...
View ArticleBharat, GSK to cut malaria vaccine price; Emergent's US stockpile deal expands
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bharat Biotech and GSK said they will reduce the price of their ...
View ArticleHandspring Health raises $12M to provide more complex care for youth
Youth virtual mental health startup Handspring Health just raised $12 million, Endpoints News has learned exclusively. Cobalt Ventures led the Series A round, with contributions from NextView Ventures,...
View ArticleWhy Commure, one of healthcare's most deal-hungry startups, plans to buy more...
Commure, one of the buzziest healthcare startups backed by General Catalyst, is hunting for more startups to buy — AI scribes included. Commure has been on a shopping spree over the past few years,...
View ArticleOpus, Viatris say presbyopia drug succeeds in Phase 3
Opus Genetics and Viatris' eye drug hit the primary endpoint in a Phase 3 study, putting them on track for an FDA filing by the end of the year. The phentolamine ophthalmic solution 0.75% program ...
View ArticleEdgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M...
Plus, news about Hummingbird, Percheron, Pfizer and I-Mab: Edgewise Therapeutics can’t get accelerated approval for muscle disease drug: The biotech said the FDA deemed its Phase 2 CANYON data...
View ArticleAltimmune posts mixed results for incretin drug in MASH; stock is halved
Altimmune said its experimental therapy for a serious fatty liver disease hit one key endpoint but not the other in a Phase 2b study. The biotech’s shares {$ALT} tanked after the ...
View Article